Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 2, 2014, Pages 127-139

  Zager, Michael G ^a,b   Kozminski, Kirk ^a,c   Pascual, Bernadette ^a   Ogilvie, Kathleen M ^a,d   Sun, Shaoxian ^a  

^a PFIZER INC   (United States)

^b Model Based Drug Development Janssen Pharmaceutical Companies of Johnson and Johnson   (United States)

^c Ferring Pharmaceuticals AS   (Denmark)

^d aTyr Pharma   (United States)

Author keywords

Allosteric; Diabetes; Glucokinase; Human PK PD prediction; PK PD modeling; Translation

Indexed keywords

ENZYME ACTIVATOR; GLUCOKINASE; GLUCOKINASE ACTIVATOR; PF 04279405; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; HUMAN; IN VITRO STUDY; MALE; MATHEMATICAL MODEL; MOUSE; MOUSE MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION;

ANIMALS; AZETIDINES; BENZOFURANS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATORS; GLUCOKINASE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, OBESE; MODELS, BIOLOGICAL;

EID: 84897581663     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9351-7     Document Type: Article

References (44)

1. Agius L, Peak M, Newgard CB, Gomez-Foix AM, Guinovart JJ (1996) Evidence for a role of glucose-induced translocation of glucokinase in the control of hepatic glycogen synthesis. J Biol Chem 271:30479-30486
2. Matschinsky FM (2005) Glucokinase, glucose homeostasis, and diabetes mellitus. Curr Diab Rep 5:171-176
3. Matschinsky FM (1990) Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 39:647-652
4. Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Näntö-Salonen K, Rahier J, López-Enriquez S, García-Gimeno MA, Sanz P, Soriguer FC, Laakso M (2004) Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes 53:2164-2168
5. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC (1998) Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338:226-230
6. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F (2002) The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 51:1240-1246
7. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF (2003) Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373
8. Grimsby J, Berthel SJ, Sarabu R (2008) Glucokinase activators for the potential treatment of type 2 diabetes. Curr Top Med Chem 8:1524-1532
9. Sarabu R, Berthel SJ, Kester RF, Tilley JW (2011) Novel glucokinase activators: a patent review (2008-2010). Expert Opin Ther Pat 21:13-33
10. Matschinsky FM, Zelent B, Doliba NM, Kaestner KH, Vanderkooi JM, Grimsby J, Berthel SJ, Sarabu R (2011) Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects. Handb Exp Pharmacol 203:357-401
11. Pfefferkorn JA, Guzman-Perez A, Litchfield J, Treadway JL, Pettersen J, Minich ML, Filipski KJ, Jones CS, Tu M, Aspnes G, Risley H, Bian J, Stevens BD, Bourassa P, D'Aquila T, Baker L, Barucci N, Robertson AS, Bourbonais F, Derksen DR, Macdougall M, Cabrera O, Chen J, Lapworth AL, Landro JA, Zavadoski WJ, Atkinson K, Haddish-Berhane N, Tan B, Yao L, Kosa RE, Varma MV, Feng B, Duignan DB, El-Kattan A, Murdande S, Liu S, Ammirati M, Knafels J, Dasilva-Jardine P, Sweet L, Liras S, Rolph TP (2012) Discovery of (S)-6-(3-cyclopentyl-2-(4- (trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotini c acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus. J Med Chem 55:1318-1333
12. Meininger GE, Scott R, Alba M, Shentu Y, Luo E, Amin H, Davies MJ, Kaufman KD, Goldstein BJ (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34:2560-2566
13. Sjostrand M, Ericsson H, Hartford M, Norjavaara E, Eriksson JW (2013) Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp. Diab Obes Metab 15:35-41
14. Morrow LA, Leonsson-Zachrisson M, Ericsson H, Wollbratt M, Knutsson M, Hompesch M, Norjavaara E (2012) Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus. Diab Obes Metab 14:1114-1122
15. Ericsson H, Roshammar D, Wollbratt M, Heijer M, Persson M, Ueda S, Leonsson-Zachrisson M, Norjavaara E (2012) Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp. Int J Clin Pharmacol Ther 50:765-777
16. Ericsson H, Sjoberg F, Heijer M, Johansson P, Wollbratt M, Norjavaara E (2012) The glucokinase activator AZD6370 decreases fasting and postprandial glucose in type 2 diabetes mellitus patients with effects influenced by dosing regimen and food. Diab Res Clin Pract 98:436-444
17. Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y (2004) Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure 12:429-438
18. Heredia VV, Thomson J, Nettleton D, Sun S (2006) Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. Biochemistry 45:7553-7562
19. Ralph EC, Thomson J, Almaden J, Sun S (2008) Glucose modulation of glucokinase activation by small molecules. Biochemistry 47:5028-5036
20. Dayneka NL, Garg V, Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478
21. Gloyn AL, Odili S, Buettger C, Njølstad PR, Shiota C, Magnuson MA, Matschinsky FM (2004) Glucokinase and the regulation of blood sugar. Glucokinase and the regulation of blood sugar. In: Matschinsky FM, Magnuson MA (eds) Glucokinase and glycemic disease: from basics to novel therapeutics, vol 16. Karger, Basel, pp 92-109
22. Efanov AM, Barrett DG, Brenner MB, Briggs SL, Delaunois A, Durbin JD, Giese U, Guo H, Radloff M, Gil GS, Sewing S, Wang Y, Weichert A, Zaliani A, Gromada J (2005) A novel glucokinase activator modulates pancreatic islet and hepatocyte function. Endocrinology 146:3696-3701
23. Ito K, Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112
24. Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K (2009) Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513-533
25. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95
26. Rooney KF, Snoeck E, Watson PH (2001) Modelling and simulation in clinical drug development. Drug Disc Today 6:802-806
27. Csajka C, Verotta D (2006) Pharmacokinetic-pharmacodynamic modelling: history and perspectives. J Pharmacokinet Pharmacodyn 33:227-279
28. Miller P (2005) Role of pharmacoeconomic analysis in R&D decision making: when, where, how? PharmacoEconomics 23:1-12
29. Agoram BM, Martin SW, van der Graaf PH (2007) The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Disc Today 12:1018-1024
30. Mea Danhof (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling for the prediction of in vivo drug concentration-effect relationships - application in drug candidate selection and lead optimization. In: Triggle DJ, Taylor JB (eds) Comprehensive medicinal chemistry II. Elsevier, Oxford, pp 885-908
31. Littman BH, Di Mario L, Plebani M, Marincola FM (2007) What's next in translational medicine? Clin Sci 112:217-227
32. Mankoff SP, Brander C, Ferrone S, Marincola FM (2004) Lost in translation: obstacles to translational medicine. J Transl Med 2:14
33. Wehling M (2008) Translational medicine: science or wishful thinking? J Transl Med 6:31
34. Mager DE, Jusko WJ (2008) Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 83:909-912
35. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518
36. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C (1980) Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes 29:979-990
37. Bergman RN (1989) Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38:1512-1527
38. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 33:313-343
39. Eddy DM, Schlessinger L (2003) Validation of the Archimedes diabetes model. Diabetes Care 26:3102-3110
40. Jauslin PM, Karlsson MO, Frey N (2012) Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin model. J Clin Pharmacol 52:1861-1871
41. Bonadonna RC, Heise T, Arbet-Engels C, Kapitza C, Avogaro A, Grimsby J, Zhi J, Grippo JF, Balena R (2010) Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study. J Clin Endocrinol Metab 95:5028-5036
42. Schneck KB, Zhang X, Bauer R, Karlsson MO, Sinha VP (2012) Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model. J Pharmacokinet Pharmacodyn 40:67-80
43. Bebernitz GR, Beaulieu V, Dale BA, Deacon R, Duttaroy A, Gao J, Grondine MS, Gupta RC, Kakmak M, Kavana M, Kirman LC, Liang J, Maniara WM, Munshi S, Nadkarni SS, Schuster HF, Stams T, Denny I, Taslimi PM, Vash B, Caplan SL (2009) Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes. J Med Chem 52:6142-6152
44. Winzell MS, Coghlan M, Leighton B, Frangioudakis G, Smith DM, Storlien LH, Ahrén B (2011) Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. Eur J Pharmacol 663:80-86